Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...

Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient ...